血清sEGFR、CEA及Cyfra21-1水平对非小细胞肺癌患者预后的影响

doi:10.6040/j.issn.1671-7554.0.2019.691

摘要/Abstract

摘要： 目的探讨非小细胞肺癌(NSCLC)患者血清可溶性表皮生长因子受体(sEGFR)、癌胚抗原(CEA)、细胞角蛋白19片段(Cyfra21-1)表达水平与总生存期的相关性。方法选取NSCLC患者127例(病理类型为鳞癌42例、腺癌85例,TNM分期为II +III期45例、IV期82例)。采用ELISA法检测血清sEGFR表达量,电化学发光法检测血清CEA、Cyfra21-1表达量,分析上述指标表达水平正常值组与异常值组NSCLC患者的临床病理特征以及与预后之间的关系。结果 NSCLC患者的sEGFR、CEA表达水平与临床分期有关联(P<0.05)。腺癌患者血清CEA显著高于鳞癌(P<0.05),血清Cyfra21-1在患者疾病一般特征中差异无统计学意义(P>0.05)。血清sEGFR降低、CEA和Cyfra21-1水平升高的患者中位总生存期分别为9.0(4.0,21.25)、8.5(4.0,16.0)和8.0(4.0,13.25)个月,与正常值组相比差异均有统计学意义(P<0.05)。结论 NSCLC患者sEGFR表达水平降低、CEA和Cyfra21-1升高与总生存期存在明显的相关性,可通过检测患者血清sEGFR、CEA、Cyfra21-1水平评估预后。

关键词: 非小细胞肺癌, 可溶性表皮生长因子受体, 癌胚抗原, 细胞角蛋白19片段, 预后

Abstract: Objective To investigate the correlation between the expression levels of serum soluble epidermal growth factor receptor(sEGFR), carcinoembryonic antigen(CEA), cytokeratin 19 fragment(Cyfra21-1), and overall survival of patients with non-small cell lung cancer(NSCLC). Methods Altogether 127 NSCLC cases were involved, including 42 cases of squamous carcinoma and 85 cases of adenocarcinoma. The TNM stage was II+III in 45 cases and IV in 82 cases. The sEGFR expression was detected with ELISA, and CEA and cyfra21-1 levels were detected with electrochemical luminescence. The relationship between the levels of sEGFR, CEA, Cyfra21-1 and the clinicopathological characteristics and prognosis of NSCLC patients were analyzed. Results The expressions of sEGFR and CEA in NSCLC patients were correlated with the clinical stage (P<0.05). Patients with adenocarcinoma showed significantly higher CEA than patients with squamous carcinoma (P<0.05), while serum Cyfra21-1 had no statistically significant characteristics (P>0.05). The median survival of patients with reduced serum sEGFR, increased CEA, and increased Cyfra21-1 was 9.0(4.0-21.25)months, 8.5(4.0, 16.0)months and 8.0(4.0, 13.25)months, respectively, which were statistically significant compared with patients with normal expressions (P<0.05). Conclusion The decrease of sEGFR, increase of CEA and Cyfra21-1 in patients with NSCLC is significantly correlated with the overall survival, and the prognosis can be assessed by detecting the serum levels of sEGFR, CEA and Cyfra21-1. 山东大学学报 (医学版)57卷10期 -徐淑媛,等.血清sEGFR、CEA及Cyfra21-1水平对非小细胞肺癌患者预后的影响 \=-

Key words: Non-small cell lung cancer, Soluble epidermal growth factor receptor, Carcinoembryonic antigen, Cytokeratin 19 fragment, Prognosis

中图分类号:

R734.2

徐淑媛,纪全江,国丽. 血清sEGFR、CEA及Cyfra21-1水平对非小细胞肺癌患者预后的影响[J]. 山东大学学报 (医学版), 2019, 57(10): 107-111.

XU Shuyuan, JI Quanjiang, GUO Li. Effects of serum levels of sEGFR, CEA and Cyfra21-1 on the prognosis of non-small cell lung cancer patients[J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 107-111.

参考文献

[1] 仰杰, 尤青海, 孟凡亮, 等. 非小细胞肺癌miR-211表达与功能初步研究[J]. 中华肿瘤防治杂志, 2018, 25(11): 773-777. YANG Jie, YOU Qinghai, MENG Fanliang, et al. Expression and function of miR-211 in non-small cell lung cancer [J]. Chinese Journal of Cancer Prevention and Treatment, 2018, 25(11): 773-777.
[2] Ye S, Chen X, Yao Y, et al. Thioredoxin reductase as a novel and efficient plasma biomarker for the detection of non-small cell lung cancer: a Large-scale, Multicenter study [J]. Sci Rep, 2019, 9(1): 2652.
[3] 吕丽婷, 刘益飞, 刘军, 等. EHD2在非小细胞肺癌中的表达及其临床意义[J]. 实用医学杂志, 2017, 33(22): 3769-3772. LV Liting, LIU Yifei, LIU Jun, et al. EHD2 expression and clinical significance in non-small cell lung cancer [J]. The Journal of Practical Medicine, 2017, 33(22): 3769-3772.
[4] 周婉婉, 梁冰, 王效静, 等. 非小细胞肺癌患者外周血hTERT mRNA水平检测的临床意义[J]. 东南大学学报(医学版), 2017, 36(2): 217-221. ZHOU Wanwan, LIANG Bing, WANG Xiaojing, et al. The level of hTERT mRNA in peripheral blood of non-small cell lung cancer detected by real-time PCR [J]. Journal Southeast University(Medical Science Edition), 2017, 36(2): 217-221.
[5] Zhang L, Liu D, Li L, et al. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonicantigen and neuron-specific enolase in lung cancer patients [J]. BMC Cancer, 2017, 17(1): 96. doi: 10.1186/s12885-017-3070-6.
[6] Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification [J]. Chest, 2017, 151(1): 193-203.
[7] Xu CH, Yang Y, Wang YC, et al. Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer [J]. Oncotarget, 2017, 8(14): 22483-22489.
[8] Shigehiro Y, Hidehito H, Kuniko SS, et al. Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer [J]. Cancer Sci, 2015,106(10): 1402-1407.
[9] Wang N, Guo H, Dong Z, et al. Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer [J]. Cancer Manage Res, 2018, 12(10): 3463-3471.
[10] Wang J, Jiang W, Zhang T, et al. Increased CYFRA 21-1, CEA and NSE are prognostic of poor outcome for locally advanced squamous cell carcinoma in lung: a nomogram and recursive partitioning risk stratificantion analysis[J]. TranslOncol, 2018, 11(4): 999-1006.
[11] Singh P, Srivastava AN, Sharma R, et al. Circulating MicroRNA-21 expression as a novel serum biomarker for oral sub-mucous fibrosis and oral squamous cell carcinoma[J]. Asian Pac JCancer Prev, 2018, 19(4): 1053-1058.
[12] He Y, Cui Y, Chang D, et al. Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma[J]. Oncotarget, 2017, 8(42): 73115-73122.
[13] Jin J, Si J, Liu Y, et al. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy[J]. Respir Res, 2018, 19(1): 197. doi: 10.1186/s12931-018-0885-x.
[14] 冯晓云, 葛琴, 陆志斌. 非小细胞肺癌患者血清miR-133b的表达水平及其临床意义探讨[J].东南大学学报(医学版), 2015, 34(6): 934-937. FENG Xiaoyun, GE Qin, LU Zhibin. Serum miR-133b levels and its relation with clinical pathological characteristics in non-small cell lung cancer patients[J]. Journal of Southeast University(Medical Science Edition), 2015, 34(6): 934-937.
[15] Zhu W, Zhou K, Zha Y, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer[J]. PLoS ONE, 2016, 11(4): e0153046. doi: 10.1371/journal.pone.0153046.
[16] Liu AM, Zhu Y, Huang ZW, et al. Long noncoding RNA FAM201A involves in radioresistance of non-small-cell lung cancer by enhancing EGFR expression via miR-370[J]. Eur Rev Med Pharmacol Sci, 2019, 23(13): 5802-5814.
[17] Filippo L, Massimiliano P, Cristian R, et al. Preliminary evidence on the diagnostic and molecular role of circulating soluble EGFR in non-small cell lung cancer[J]. Mol Sci, 2015, 16(8): 19612-19630.
[18] Hui R, Yang H, Tao X, et al. Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer[J]. Oncol Lett, 2019, 18(4): 4167-4175.
[19] Romero-Ventosa EY, Blanco-Prieto S, González-Pi(~overn)eiro AL, et al. Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients [J]. Springer Plus, 2015, 9(4): 171. doi: 10.1186/s40064-015-0891-0. eCollection 2015.
[20] Dai L, Qu Y, Li J, et al. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer [J]. Oncotarget, 2017, 8(22): 36664-36673.
[21] Dal Bello MG, Filiberti RA, Alama A, et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer(NSCLC)patients [J]. J Transl Med, 2019, 17(1): 74. doi: 10.1186/s12967-019-1828-0.
[22] Mauro C, Passerini R, Spaggiari L, et al. New and old biomarkers in the differential diagnosis of lung cancer: pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1 [J]. Int J Biol Markers, 2019, 34(2):163-167.
[23] Wang XB, Li J, Han Y. Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a metaanalysis[J]. Tumor Biol, 2014, 35(10): 10105-10110.
[24] Baek AR, Seo HJ, Lee JH, et al. Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer [J]. Cancer Biomarker, 2018, 22(1): 55-62.
[25] Parka SY, Leea JG, Kimb J, et al. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung [J]. Lung Cancer, 2013, 79(2): 156-160.

相关文章 15

[1]	黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.
[2]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[3]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[4]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[5]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[6]	赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85.
[7]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[8]	杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[9]	徐年兴,魏东,乔俊杰,战炳炎. CD8⁺、IL-6和PaO₂对不可切除Ⅲ_B/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[10]	山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5.
[11]	刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[12]	刘振昆,吕纪玲,徐伟伟,马力天,张才擎. BALF tNGS检测及培养对NSCLC合并IPFD的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(11): 36-45.
[13]	陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[14]	郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16.
[15]	张荣雨,赵文,李洪欣,杨闯,王健,韩春燕,李际盛. 奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报 (医学版), 2024, 62(5): 116-120.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed